Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tafamidis
Pharma
Pfizer's ATTR drug again faces pricing scrutiny
Pfizer’s tafamidis needs a minimum 85% discount from its annual list price to meet commonly accepted cost-effectiveness thresholds, ICER says.
Angus Liu
Oct 21, 2024 2:55pm
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
Aug 30, 2024 10:06am
Pfizer's ATTR drug needs hefty discount, says ICER draft report
Jul 18, 2024 4:37pm
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Apr 22, 2024 10:55am
Alnylam's last-minute Amvuttra trial change raises doubts
Feb 15, 2024 11:26am
FDA spurns Alnylam's Onpattro in ATTR-CM despite adcomm backing
Oct 9, 2023 9:54am
